A Phase 2 Trial of Myocet, Cyclophosphamide +/- Trastuzumab Followed by Weekly Paclitaxel +/- Trastuzumab as Primary Systemic Therapy in Operable and Locally Advanced Breast Cancer

Trial Profile

A Phase 2 Trial of Myocet, Cyclophosphamide +/- Trastuzumab Followed by Weekly Paclitaxel +/- Trastuzumab as Primary Systemic Therapy in Operable and Locally Advanced Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2014

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top